Clearside Biomedical, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- George Lasezkay
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 900 North Point Parkway Alpharetta GA United States of America 30005
- IPO Date
- Jun 2, 2016
- CIK
- 0001539029
- Website
- clearsidebio.com
- Similar Companies
- Business
- Clearside Biomedical, Inc. engages in the development and delivery of therapies for retinal and choroidal diseases through its suprachoroidal space (SCS) Microinjector platform. The company focuses on ophthalmic therapeutics, combining a proprietary in-office injection technology with a pipeline of drug candidates and formulations designed for targeted, non-surgical administration to the back of the eye. Main products and services: - SCS Microinjector platform: in-office, repeatable, non-surgical delivery system enabling focal administration of therapies to the retina and choroid via the suprachoroidal space; supports a broad range of existing and investigational compounds. - XIPERE (triamcinolone acetonide injectable suspension): suprachoroidal delivery formulation approved for certain ocular indications; distributed in the United States through a commercial partner. - CLS-AX (axitinib injectable suspension): a small-molecule anti-angiogenic candidate for neovascular, or wet, age-related macular degeneration (AMD); part of the company’s ongoing clinical development program. - In-house and partnered drug candidates for suprachoroidal delivery: various formulations and collaborations aiming to advance therapies to the back of the eye for chronic, vision-threatening diseases. - Platform services and collaboration opportunities: development and optimization of SCS Microinjector-based delivery for third-party and partner programs, including clinical development support and feasibility assessments. Latest major company changes: - Strategic alignment and plan updates for Phase 3 development of CLS-AX in wet AMD, including FDA interactions and development plans; reflects a shift toward advancing late-stage trials and potential regulatory submissions. - Ongoing exploration of strategic alternatives and partnerships, including potential acquisitions or strategic transactions as part of corporate restructuring and capital optimization efforts. - Continued advancement of partner-driven suprachoroidal programs using the SCS Microinjector, with updates signaling emphasis on non-surgical, targeted ocular drug delivery and expansion of the company’s clinical collaboration footprint. - Ongoing efforts to monetize or restructure existing assets, including evaluating strategic options for the company’s product portfolio and pipeline in light of market and regulatory developments. Additional context: - Industry focus: ophthalmology, with emphasis on back-of-the-eye drug delivery and targeted therapies for retinal and choroidal diseases. - Business segments: internal development of ophthalmic drugs and delivery technologies; collaboration and licensing arrangements with pharmaceutical partners; potential commercialization via strategic partnerships. - Geographic operations: primarily United States activities with potential global commercialization via partners; headquartered in the United States with clinical operations and partner networks likely across multiple regions. - Founding year and headquarters: established in the early 2000s; headquarters located in the United States. - Subsidiaries/parent relationships: operates as an independent biopharmaceutical company with potential partner and contract development arrangements; may have associated entities for manufacturing, regulatory affairs, and distribution through collaborations.
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Hold” from Brokerages
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update